Andrew Wilkins > Dechert LLP > Boston, United States > Lawyer Profile
Dechert LLP Offices
ONE INTERNATIONAL PLACE
40TH FLOOR, 100 OLIVER STREET
BOSTON, MA 02110-2605
MASSACHUSETTS
United States
- Firm Profile
- Go to...
Andrew Wilkins
Work Department
Intellectual Property
Position
Partner
Career
Andrew T. Wilkins, Ph.D. is a partner in Dechert’s intellectual property group, focusing his practice on patent law relating to biotechnology. Dr. Wilkins has extensive experience representing biotech companies and investors in strategic international patent portfolio development and life cycle management, as well as non-infringement and invalidity analysis, post-grant proceedings and IP due diligence.
Dr. Wilkins has advised clients on matters relating to an array of biotech areas, including: therapeutic antibodies and antibody-like molecules for oncology, autoimmune, cardiovascular and infectious disease indications; immunotherapy, including CAR and recombinant TCR technologies, peptide-based vaccines and immune checkpoint antibodies; antibody and TCR discovery and engineering technologies; glycoengineering technologies, including antibody Fc glycoengineering technologies; viral delivery technologies, including lentiviral and AAV delivery technologies; gene therapy technologies, including gene replacement and gene editing technologies; biocompatible drug delivery vehicles, including controlled release nanoparticle liposome technologies; drug screening assays; RNAi technologies; and Bayh-Dole compliance in the acquisition or licensing of IP based upon NIH-funded research.
In addition to his practice, Dr. Wilkins has prolific academic and industrial research experience, his previous roles including: an instructor in medicine at Harvard Medical School/Beth Israel Deaconess Medical Center in Boston; a graduate research student with GlaxoSmithKline, UK; a postdoctoral research associate with MRC Laboratory of Molecular Biology, UK; and an undergraduate research student with Celltech PLC, UK. He has authored/co-authored numerous scientific articles in top peer-reviewed journals, such as Genes and Development, Current Biology, Biochemical Journal, Genome Biology, Cell Motility and the Cytoskeleton, Trends in Genetics and Methods in Enzymology.
Education
- University of Glasgow, B.Sc., Biochemistry
- University of London, Ph.D., Molecular Cell Biology
- Suffolk University Law School, J.D.
Lawyer Rankings
United States > Intellectual property > Patents: prosecution (including re-examination and post-grant proceedings)
Dechert LLP‘s Boston-based practice is co-led by Andrea Reid and Andrew Wilkins, who is described as ‘one of the best IP counsel’. The team is adept at advising on prosecution in a multitude of areas, though there is an evident expertise across the board in biotech, with the team being noted as a ‘terrific partner when it comes to new technologies’. Additionally, its work in life sciences and pharmaceuticals is noteworthy, a key example being Reid and the ‘business-centric’ and ‘excellent’ Chad Davis representing AVEO Oncology on the $566m multi-jurisdictional creation of its patent portfolio following its acquisition by LG Chem. Scott Warren left the firm in August 2022.
Lawyer Rankings
Top Tier Firm Rankings
- Intellectual property > Trademarks: non-contentious (including prosecution, portfolio management and licensing)
- Labor and employment > Employee benefits, executive compensation and retirement plans: transactional
- Investment fund formation and management > Mutual/registered/exchange-traded funds
- Dispute resolution > Product liability, mass tort and class action - defense: pharmaceuticals and medical devices
- Real estate > Real estate finance
Firm Rankings
- Media, technology and telecoms > Cyber law (including data privacy and data protection)
- Dispute resolution > Product liability, mass tort and class action - defense: toxic tort
- Dispute resolution > Securities litigation: defense
- Finance > Structured finance: securitization
- Antitrust > Civil litigation/class actions: defense
- Dispute resolution > E-discovery
- Finance > Fintech
- Dispute resolution > General commercial disputes
- Dispute resolution > International litigation
- Tax > International tax
- Healthcare > Life sciences
- Dispute resolution > M&A litigation: defense
- Antitrust > Merger control
- M&A/corporate and commercial > Private equity buyouts: large deals ($500m+)
- Dispute resolution > Product liability, mass tort and class action - defense: consumer products (including tobacco)
- Finance > Restructuring (including bankruptcy): corporate
- Tax > US taxes: non-contentious
- Finance > Capital markets: debt offerings
- Finance > Capital markets: equity offerings
- Finance > Capital markets: global offerings
- Labor and employment > Employee benefits, executive compensation and retirement plans: transactional
- Environment > Environment: transactional
- Dispute resolution > International arbitration
- M&A/corporate and commercial > M&A: large deals ($1bn+)
- Intellectual property > Patents: prosecution (including re-examination and post-grant proceedings)
- International Trade > Customs, export controls and economic sanctions
- Dispute resolution > Leading trial lawyers
- Intellectual property > Patents: litigation (full coverage)
- Investment fund formation and management > Private equity funds (including venture capital)
- Finance > Capital markets: high-yield debt offerings
- Finance > Commercial lending
- Dispute resolution > Corporate investigations and white-collar criminal defense
- Dispute resolution > Financial services litigation